Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Scholar Rock Holding ( (SRRK) ) has shared an update.
Scholar Rock Holding Corporation announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, where it will present its strategic advancements and future plans. The company is progressing with the development and potential commercialization of apitegromab, a promising therapy for spinal muscular atrophy (SMA), after successful Phase 3 trial results. With a focus on expanding its pipeline, Scholar Rock aims to submit regulatory filings for apitegromab in early 2025 and explore additional indications, positioning itself as a leader in the treatment of SMA and related conditions.
More about Scholar Rock Holding
Scholar Rock Holding Corporation is engaged in the biopharmaceutical industry, focusing on the discovery and development of innovative therapies for serious diseases. The company specializes in targeting latent growth factors to create transformative treatments, particularly in areas such as neuromuscular disorders, cardiometabolic conditions, and oncology.
YTD Price Performance: -3.53%
Average Trading Volume: 1,111,075
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.79B
See more data about SRRK stock on TipRanks’ Stock Analysis page.
